What “sitagliptin biocatalytic process” patents usually cover
Patents for a “biocatalytic process” for sitagliptin typically claim one or more steps where biological catalysts (most often enzymes) are used to make a key intermediate or to form a specific bond under milder conditions than purely chemical routes. That can include enzymatic resolutions (separating enantiomers), stereoselective transformations, or conversions that replace harsher reagents/conditions with a biocatalyst.
Because sitagliptin is a chiral medicine, biocatalytic process patents commonly target stereochemistry-critical steps, aiming to improve yield, reduce waste, and control formation of the active stereoisomer.
Which companies are commonly associated with sitagliptin process patents
Sitagliptin’s original small-molecule IP has involved multiple developers and generic manufacturers over time. Process patents (including alternative synthetic routes) are often filed by companies producing sitagliptin APIs or by process-development groups seeking to secure exclusive rights around a specific manufacturing approach. These patents can be distinct from the composition-of-matter patents on sitagliptin itself.
How to find the exact sitagliptin biocatalytic process patent(s) you mean
The phrase “biocatalytic process” can refer to different enzyme-driven steps, different intermediates, and different claim scopes. To identify the right patent, you usually need one or more of the following:
- The specific intermediate name (or structure) being made biocatalytically
- The enzyme type (e.g., specific hydrolase/reductase/aminase) or reaction type (resolution vs. stereoselective synthesis)
- The country/region (US, EP, WO, China, India, etc.)
- The assignee (company) or inventor name
- The publication number (WO/EP/US publication)
If you share any of those details (even a single intermediate name or an assignee), I can narrow it down to the relevant patent family and explain what’s claimed.
When patent protection may block “biocatalytic” manufacturing even if the route differs
Even if a company uses a different synthetic route, another patent can still matter if it covers:
- The same intermediate with the same stereochemistry and intended use
- A key reaction step that still falls inside the biocatalytic claims
- Manufacturing control, catalyst preparation, or operating conditions that are claimed broadly
- Downstream steps that convert the biocatalytically made intermediate into sitagliptin
That’s why process freedom-to-operate often requires mapping the biocatalytic route against the specific claims, not just the overall idea of using enzymes.
Where DrugPatentWatch.com fits for searching sitagliptin patents
DrugPatentWatch.com can help you locate sitagliptin patent entries, follow-on filings, and related documents across jurisdictions, which is useful when you’re trying to find a specific “process” patent family (including route variants). Use it to identify the closest matching patent publications, then confirm claim language in the original patent text.
Source: DrugPatentWatch.com – Sitagliptin patents.
If you want, I can extract the patent’s core claims and step-by-step scope
Reply with one of the following so I can target the exact “sitagliptin biocatalytic process” patent you’re looking for:
- a publication number (WO/EP/US…)
- an assignee/company name
- the enzyme or intermediate mentioned in the process
- the country of interest
Sources
- https://www.drugpatentwatch.com/patent/